#For patients
Written for adults considering a peptide as part of their health management.
Tirzepatide vs GLP-1RAs and IBD risk
A US propensity-matched study found tirzepatide linked to fewer IV steroid courses than other GLP-1 drugs among patients who already have IBD.
What BPC-157 actually costs in the UK
BPC-157 has no UK licence, so there is no NHS price and no NICE appraisal. The only UK cost is grey-market research-chemical listings sold for research use.
Why Dying Liver Cells Drive MASH
A 2026 review explains how cell death fuels MASH, the liver disease semaglutide became the first FDA-approved drug to treat.
GLP-1 Drugs, PCOS, and Stopping Treatment
Some GLP-1 users say PCOS symptoms return after stopping treatment. Here is what the semaglutide and retatrutide trial data actually shows.
Semaglutide and tirzepatide for MASH
Semaglutide now has FDA approval for MASH liver fibrosis, and tirzepatide's phase 2 data suggests a stronger signal is coming.
GLP-1 Drugs and Skin Cancer Risk
A new Dermatologic Surgery paper links semaglutide and tirzepatide to lower skin cancer rates in patients with obesity, but the abstract isn't public yet.
Semax/Selank blend: the dosing math gap
Semax/Selank blend dosing math fails for one reason: the vial never states how much of each peptide it actually contains.
Testing Tirzepatide After Gastric Bypass
A Vanderbilt pilot trial called GRABS is testing tirzepatide in patients whose obesity persists after gastric bypass surgery.
Can you drink alcohol on tirzepatide?
The tirzepatide label lists no alcohol interaction and no trial has tested the combination. Here is where the two sets of risks actually overlap.
PT-141 microdosing: what the label says
Daily sub-label PT-141 schedules sit outside the Vyleesi label and well below the lowest dose ever taken into a published controlled trial.
Does tirzepatide cut carpal tunnel risk?
A 2026 cohort study links tirzepatide to fewer carpal tunnel diagnoses than other weight drugs. That is an association, not a treatment effect.
Why GLP-1 prescriptions go unfilled
About 40% of GLP-1 orders are never dispensed. Here is what the fill-rate evidence on semaglutide and tirzepatide shows, and what it cannot show.